Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QA7 | ISIN: US80880X1046 | Ticker-Symbol: 4E4
Tradegate
25.06.25 | 16:20
0,835 Euro
-1,76 % -0,015
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SCIENTURE HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SCIENTURE HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7950,84019:28

Aktuelle News zur SCIENTURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Scienture Holdings terminates equity line of credit ahead of product launch1
17.06.Scienture Holdings, Inc.: Scienture Holdings Announces Cancelation of ELOC2
22.05.Scienture appoints Hariharan, Mani as co-CEOs1
22.05.Scienture Holdings, Inc.: SCIENTURE Announces Executive Leadership Transition1
19.05.Scienture Holdings, Inc.: SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.136TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value...
► Artikel lesen
SCIENTURE Aktie jetzt für 0€ handeln
12.05.Scienture Holdings, Inc. - 10-Q, Quarterly Report2
22.04.Scienture Holdings, Inc.: SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.1
08.04.Scienture Holdings veräußert Tochtergesellschaften für 5 Millionen US-Dollar1
08.04.Scienture Holdings divests subsidiaries for $5 million2
08.04.Scienture Holdings, Inc.: SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.2
04.04.Scienture Holdings files to sell 2.64M shares of common stock for holders1
04.04.Scienture Holdings, Inc. - S-1, General form for registration of securities1
03.04.Scienture Holdings gears up for specialty pharma launches1
03.04.Scienture Holdings bereitet sich auf Markteinführungen von Spezialpharmaka vor1
03.04.Scienture Holdings, Inc. Issues Annual Letter to Shareholders239TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value...
► Artikel lesen
25.03.Scienture Holdings, Inc.: SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization2
21.03.Scienture Holdings, Inc. - 8-K, Current Report1
19.03.Scienture Holdings announces draw on Equity Line of Credit2
19.03.Scienture Holdings, Inc.: Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days1
18.03.What's Going On With Scienture Shares Tuesday?1
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1